Pulmatrix PULM Stock
Pulmatrix Price Chart
Pulmatrix PULM Financial and Trading Overview
| Pulmatrix stock price | 2.16 USD |
| Previous Close | 2.71 USD |
| Open | 2.7 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.64 - 2.77 USD |
| 52 Week Range | 2.62 - 7.5 USD |
| Volume | 8.73K USD |
| Avg. Volume | 15.79K USD |
| Market Cap | 10.12M USD |
| Beta (5Y Monthly) | 0.752112 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.87 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10 USD |
PULM Valuation Measures
| Enterprise Value | -20222400 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.5420743 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.5782864 |
| Price/Book (mrq) | 0.3745774 |
| Enterprise Value/Revenue | -3.155 |
| Enterprise Value/EBITDA | 1.098 |
Trading Information
Pulmatrix Stock Price History
| Beta (5Y Monthly) | 0.752112 |
| 52-Week Change | -33.73% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.5 USD |
| 52 Week Low | 2.62 USD |
| 50-Day Moving Average | 2.82 USD |
| 200-Day Moving Average | 3.47 USD |
PULM Share Statistics
| Avg. Volume (3 month) | 15.79K USD |
| Avg. Daily Volume (10-Days) | 11.56K USD |
| Shares Outstanding | 3.65M |
| Float | 3.43M |
| Short Ratio | 0.31 |
| % Held by Insiders | 0.0020% |
| % Held by Institutions | 20.16% |
| Shares Short | 4.8K |
| Short % of Float | 0.13% |
| Short % of Shares Outstanding | 0.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -285.66% |
| Operating Margin (ttm) | -289.68% |
| Gross Margin | -180.26% |
| EBITDA Margin | -287.20% |
Management Effectiveness
| Return on Assets (ttm) | -25.68% |
| Return on Equity (ttm) | -52.49% |
Income Statement
| Revenue (ttm) | 6.41M USD |
| Revenue Per Share (ttm) | 1.81 USD |
| Quarterly Revenue Growth (yoy) | 29.19% |
| Gross Profit (ttm) | 6.07M USD |
| EBITDA | -18410000 USD |
| Net Income Avi to Common (ttm) | -18311000 USD |
| Diluted EPS (ttm) | -5.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.75M USD |
| Total Cash Per Share (mrq) | 8.42 USD |
| Total Debt (mrq) | 779K USD |
| Total Debt/Equity (mrq) | 2.88 USD |
| Current Ratio (mrq) | 6.932 |
| Book Value Per Share (mrq) | 7.395 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18140000 USD |
| Levered Free Cash Flow (ttm) | -7814625 USD |
Profile of Pulmatrix
| Country | United States |
| State | MA |
| City | Lexington |
| Address | 99 Hayden Avenue |
| ZIP | 02421 |
| Phone | 781 357 2333 |
| Website | https://www.pulmatrix.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 28 |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Q&A For Pulmatrix Stock
What is a current PULM stock price?
Pulmatrix PULM stock price today per share is 2.16 USD.
How to purchase Pulmatrix stock?
You can buy PULM shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pulmatrix?
The stock symbol or ticker of Pulmatrix is PULM.
Which industry does the Pulmatrix company belong to?
The Pulmatrix industry is Biotechnology.
How many shares does Pulmatrix have in circulation?
The max supply of Pulmatrix shares is 3.65M.
What is Pulmatrix Price to Earnings Ratio (PE Ratio)?
Pulmatrix PE Ratio is now.
What was Pulmatrix earnings per share over the trailing 12 months (TTM)?
Pulmatrix EPS is -3.87 USD over the trailing 12 months.
Which sector does the Pulmatrix company belong to?
The Pulmatrix sector is Healthcare.
Pulmatrix PULM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}